Differential sensitivities of pathogens in red cell concentrates to Tri-P(4)-photoinactivation

Vox Sanguinis

Volumn 91, Issue 2, 2006, Pages 111-118

  Trannoy, L L ^a   Terpstra, F G ^b   De Korte, D ^b   Lagerberg, J W M ^b   Verhoeven, A J ^b   Brand, A ^a   Van Engelenburg, F A C ^b  

^a Sanquin Blood Bank Southwest ^*  (Netherlands)

^b Sanguin Research   (Netherlands)

Author keywords

Bacteria; Cell death; Pathogen inactivation; Photodynamic treatment; Porphyin; Red blood cells; Viruses

Indexed keywords

ADENOSINE TRIPHOSPHATE; LIPID; PHENYLTRIS(N METHYL 4 PYRIDYL)PORPHYRIN CHLORIDE; PORPHYRIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM; BLOOD STORAGE; BOVINE DIARRHEA VIRUS; CELL DEATH; CONTROLLED STUDY; ERYTHROCYTE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEMOLYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; KINETICS; NONHUMAN; PARVOVIRUS; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDORABIES HERPETOVIRUS; STAPHYLOCOCCUS AUREUS; VIRUS; YERSINIA ENTEROCOLITICA;

ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; BLOOD PRESERVATION; CELL DEATH; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; HEMATOPORPHYRIN PHOTORADIATION; HUMANS; PHOTOSENSITIZING AGENTS; PORPHYRINS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STERILIZATION; VIRUS INACTIVATION; VIRUSES; YERSINIA ENTEROCOLITICA;

EID: 33746396588     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2006.00791.x     Document Type: Article

References (35)

1. Barbara J: Why 'Safer than ever' may not be quite safe enough. Transfus Med Hemother 2004; 31:2-10
2. Delwart EL, Kalmin ND, Jones TS, Ladd DJ, Foley B, Tobler LH, Tsui RCP, Busch MP: First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sang 2004; 86:171-177
3. Cesaire R, Kerob-Bauchet B, Bourdonne O, Maier H, Amar KO, Halbout P, Dehee A, Desire N, Dantin F, Bera O, Lezin A: Evaluation of HTLV-I removal by filtration of blood cell components in a routine setting. Transfusion 2004; 44:42-48
4. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M: Transfusion- transmitted cytomegalovirus infection after receipt of leuko-reduced blood products. Blood 2003; 101:4195-4200
5. Wüllenweber J, Cassens U, Sica S, Sibrowski W, Herrmann M: West Nile virus - an emerging transfusion-transmissible pathogen. Transfus Med Hemother 2004; 31:373-377
6. Seifried E, Mueller MM: European Parliamentary Public Hearing on the impact of SARS and other emerging pathogens on transfusion medicine. Blood Ther Med 2003; 3:109-110
7. Rox JM, Eis-Hubinger AM, Muller J, Vogel M, Kaiser R, Hanfland P, Daumer M: First human immunodeficiency virus-1 group O infection in a European blood donor. Vox Sang 2004; 87:44-45
8. Andreu G, Morel P, Forestier F, Debeir J, Rebibo D, Janvier G, Herve P: Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion 2002; 42:1356-1364
9. Stainsby D, Cohen H, Jones H: Haemovigilance in the UK - the Shot scheme. Blood Bank Transfus Med 2004; 2:27-30
10. Wagner SJ: Transfusion-transmitted bacterial infection: risks, sources and interventions. Vox Sang 2004; 86:157-163
11. Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby D, Lin L, Stramer S: Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005; 19:110-126
12. Cook D: In vivo analysis of packed red blood cells treated with S-303 to inactivate pathogens. Blood 1998; 92:10 (503a)
13. Purmal A, Valeri CR, Dzik W, Pivacek L, Ragno G, Lazo A, Chapman J: Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies. Transfusion 2002; 42:139-145
14. Cerus Co., Baxter International Inc.: Baxter And Cerus Halt Red Blood Cell Clinical Trials For Investigational Pathogen Inactivation System. Berlin: Chemie DE GmBH, 2003 [available at http://www.bionity.com (accessed 09/05/2003)]
15. V.I.Technologies I: Vitex halts enrollment in Phase III Chronic Trial of the Inactine Pathogen Reduction System for Red Blood Cells. Roanoke: Blue Ridge Business Journal, 2003 [available at http://www.bizjournal.com (accessed 18/11/2003)]
16. Malik Z, Hanania J, Nitzan Y: Bactericidal effects of photoactivated porphyrins - an alternative approach to antimicrobial drugs. J Photochem Photobiol B 1990, 2003; 5:281-293
17. VanSteveninck J, Trannoy LL, Besselink GAJ, Dubbelman TMAR, Brand A, de Korte D, Verhoeven AJ, Lagerberg JWM: Selective protection of erythrocytes against photodynatnic damage by the band 3 ligand Dipyridamol. Transfusion 2000; 40:1330-1336
18. Wagner SJ: Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev 2002; 16:61-66
19. Rywkin S, Ben-Hur E, Malik Z, Prince AM, Li YS, Kenney ME, Oleinick NL, Horowitz B: New phthalocyanines for photodynamic virus inactivation in red blood cell concentrates. Photochem Photobiol 1994; 60:165-170
20. Lagerberg JWM, Uberriegler KP, Krammer B, VanSteveninck J, Dubbelman TM: Plasma membrane properties involved in the photodynamic efficacy of merocyanine 540 and tetrasulfonated aluminum phthalocyanine. Photochem Photobiol 2000; 71:341-346
21. North J, Neyndorff H, Levy JG: Photosensitizers as virucidal agents. J Photochem Photobiol B 1993; 17:99-108
22. Trannoy LL, Lagerberg JWM, Dubbelman TMAR, Schuitmaker JJ, Brand A: Positively charged porphyrins: a new series of photosensitizers for sterilization of RBCs. Transfusion 2004; 44:1186-1196
23. Miles AA, Misra SS: The estimation of the bactericidal power of the blood. J Hyg 1938; 38:732-749
24. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA: Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 1997; 71:3023-3030
25. Ben-Hur E, Chan WS, Yim Z, Zuk MM, Dayal V, Roth N, Heldman E, Lazo A, Valeri CR, Horowitz B: Photochemical decontamination of red blood cell concentrates with the silicon phthalocyanine PC 4 and red light. Dev Biol Stand 2000; 102:149-155
26. Gould SJ, Booth AM, Hildreth JE: The Trojan exosome hypothesis. Proc Natl Acad Sci USA 2003; 100:10592-10597
27. Margolis-Nunno H, Ben-Hur E, Gottlieb P, Robinson R, Oetjen J, Horowitz B: Inactivation by phthalocyanine photosensitization of multiple forms of human immunodeficiency virus in red cell concentrates. Transfusion 1996; 36:743-750
28. Hayashi S, Ogawa S, Takashima Y, Otsuka H: The neutralization of pseudorabies virus by anti-alpha-galactocyl natural antibody in normal serum. Virus Res 2004; 99:1-7
29. Mohr H, Bachmann B, Klein-Struckmeier A, Lambrecht B: Virus inactivation of blood products by phenothiazine dyes and light. Photochem Photobiol 1997; 65:441-445
30. Käsermann F, Kempf C, Boschetti N: Strengths and limitations of the model virus concept. PDA J Pharm Sci Technol 2004; 58:244-249
31. Koppelman MHGM, Sjerps MC, Reesink HW, Cuypers HTM: Evaluation of COBAS AmpliPrep nucleic acid extraction in conjunction with COBAS AmpliScreen HBV DNA, HCV RNA and HIV-1 RNA amplification and detection. Vox Sang 2005; 89:193-200
32. Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K: Hepatitis B NAT virus-positive blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang 2005; 88:77-86
33. Weusten JJ, van Drimmelen HA, Lelie PN: Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002; 42:537-548
34. Lambrechts SA, Aalders MC, Van Marle J: Mechanistic study of photodynamic inactivation of Candida albicans by a cationic porphyrin. Antimicrob Agents Chemother 2005; 49:2026-2034
35. Merchat M, Spikes JD, Bertoloni G, Jori G: Studies on the mechanism of bacteria photosensitization by meso-substituted cationic porphyrins. J Photochem Photobiol B 1996; 35:149-157